245 related articles for article (PubMed ID: 25870060)
1. Blocking Hsp70 enhances the efficiency of amphotericin B treatment against resistant Aspergillus terreus strains.
Blatzer M; Blum G; Jukic E; Posch W; Gruber P; Nagl M; Binder U; Maurer E; Sarg B; Lindner H; Lass-Flörl C; Wilflingseder D
Antimicrob Agents Chemother; 2015 Jul; 59(7):3778-88. PubMed ID: 25870060
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo role of heat shock protein 90 in Amphotericin B resistance of Aspergillus terreus.
Blum G; Kainzner B; Grif K; Dietrich H; Zeiger B; Sonnweber T; Lass-Flörl C
Clin Microbiol Infect; 2013 Jan; 19(1):50-55. PubMed ID: 22515428
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B Resistance in Aspergillus terreus Is Overpowered by Coapplication of Pro-oxidants.
Blatzer M; Jukic E; Posch W; Schöpf B; Binder U; Steger M; Blum G; Hackl H; Gnaiger E; Lass-Flörl C; Wilflingseder D
Antioxid Redox Signal; 2015 Dec; 23(18):1424-38. PubMed ID: 26054424
[TBL] [Abstract][Full Text] [Related]
4. Impact of Morphological Sectors on Antifungal Susceptibility Testing and Virulence Studies.
Jukic E; Blatzer M; Binder U; Mayr L; Lass-Flörl C; Lackner M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993330
[TBL] [Abstract][Full Text] [Related]
5. Aspergillus terreus: Novel lessons learned on amphotericin B resistance.
Posch W; Blatzer M; Wilflingseder D; Lass-Flörl C
Med Mycol; 2018 Apr; 56(suppl_1):73-82. PubMed ID: 29538736
[TBL] [Abstract][Full Text] [Related]
6. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
7. Galleria mellonella as a host model to study Aspergillus terreus virulence and amphotericin B resistance.
Maurer E; Browne N; Surlis C; Jukic E; Moser P; Kavanagh K; Lass-Flörl C; Binder U
Virulence; 2015; 6(6):591-8. PubMed ID: 26107350
[TBL] [Abstract][Full Text] [Related]
8. Antifungal resistance in Aspergillus terreus: A current scenario.
Vahedi Shahandashti R; Lass-Flörl C
Fungal Genet Biol; 2019 Oct; 131():103247. PubMed ID: 31247322
[TBL] [Abstract][Full Text] [Related]
9.
Vahedi-Shahandashti R; Dietl AM; Binder U; Nagl M; Würzner R; Lass-Flörl C
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0227421. PubMed ID: 35254091
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
12. Oxidative Stress Response Tips the Balance in Aspergillus terreus Amphotericin B Resistance.
Jukic E; Blatzer M; Posch W; Steger M; Binder U; Lass-Flörl C; Wilflingseder D
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739793
[TBL] [Abstract][Full Text] [Related]
13. New insight into amphotericin B resistance in Aspergillus terreus.
Blum G; Hörtnagl C; Jukic E; Erbeznik T; Pümpel T; Dietrich H; Nagl M; Speth C; Rambach G; Lass-Flörl C
Antimicrob Agents Chemother; 2013 Apr; 57(4):1583-8. PubMed ID: 23318794
[TBL] [Abstract][Full Text] [Related]
14. Potential basis for amphotericin B resistance in Aspergillus terreus.
Blum G; Perkhofer S; Haas H; Schrettl M; Würzner R; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Apr; 52(4):1553-5. PubMed ID: 18268082
[TBL] [Abstract][Full Text] [Related]
15. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
16. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.
Fakhim H; Badali H; Dannaoui E; Nasirian M; Jahangiri F; Raei M; Vaseghi N; Ahmadikia K; Vaezi A
J Mycol Med; 2022 Nov; 32(4):101310. PubMed ID: 35907396
[TBL] [Abstract][Full Text] [Related]
17. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
[TBL] [Abstract][Full Text] [Related]
18. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
[TBL] [Abstract][Full Text] [Related]
20. Diversity of clinical isolates of Aspergillus terreus in antifungal susceptibilities, genotypes and virulence in Galleria mellonella model: Comparison between respiratory and ear isolates.
Won EJ; Choi MJ; Shin JH; Park YJ; Byun SA; Jung JS; Kim SH; Shin MG; Suh SP
PLoS One; 2017; 12(10):e0186086. PubMed ID: 29016668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]